23andMe and its customers’ genetic data bought by a pharmaceutical org

Regeneron Pharmaceuticals acquired bankrupt genetic testing company 23andMe for $256 million, primarily to expand its genetic data resources, adding 23andMe's 15 million customers to Regeneron's existing database of nearly three million. The acquisition raises ethical and privacy concerns regarding the use of sensitive genetic information, though Regeneron has pledged to uphold data privacy with oversight from a court-appointed Customer Privacy Ombudsman. Customers are advised to actively manage their data, including deleting it, destroying samples, or revoking research permissions, and to check for exposure in the 2023 data breach.

Analysis

Regeneron Pharmaceuticals (REGN) has acquired the bankrupt genetic testing firm 23andMe for $256 million, a strategic move primarily aimed at accessing 23andMe's extensive genetic database of 15 million customers. This acquisition significantly expands Regeneron's existing genetic data resources, which currently cover nearly three million individuals, and is expected to bolster its pharmaceutical research pipeline and personalized medicine initiatives by leveraging 23andMe's consumer genetics business infrastructure and research services. Despite the strategic benefits, the transaction surfaces considerable ethical, privacy, and security concerns, particularly as consumer genetic data, unlike traditional medical records protected under HIPAA, is covered primarily by consumer privacy laws offering weaker protections. Regeneron has pledged to uphold data privacy and security, working with a court-appointed Customer Privacy Ombudsman, yet concerns persist, highlighted by Senator Cassidy's apprehension about potential foreign access to sensitive American genetic data. The general market sentiment surrounding the deal is neutral (sentiment score -0.1) with a cautious tone, reflecting these complexities, although sentiment specifically for REGN is slightly positive (0.4), indicating perceived long-term benefits for the acquirer despite the inherent risks.

Key Decisions for Investors

• Investors in Regeneron (REGN) should view this acquisition as a strategic enhancement to its R&D capabilities through a significantly expanded genetic dataset, but must closely monitor regulatory scrutiny, public perception regarding data privacy, and the integration of 23andMe's operations, as these factors could pose reputational and financial risks.
• The deal underscores the increasing valuation of large-scale human genetic data in the biotechnology and pharmaceutical sectors, potentially signaling further M&A activity involving companies with substantial data assets, alongside an intensified focus on data governance and ethical considerations.
• Consider the heightened risk profile associated with companies managing extensive consumer genetic data, including potential liabilities from data breaches, such as the 2023 23andMe incident, and the impact of evolving privacy legislation, which may warrant adjustments to portfolio allocations in this sub-sector.